MonumenTAL-6 Key Takeaways
Progression-free survival (primary endpoint)
Teclistamab + talquetamab: hazard ratio 0.11 (95% CI 0.08–0.16; p<0.0001) — an 89% reduction in the risk of progression or death, versus investigator's choice of EPd or PVd. (J&J topline release)
Talquetamab + pomalidomide: hazard ratio 0.27 (95% CI 0.2–0.35) — a 73% reduction in the risk of progression or death. No p-value disclosed, and no overall-survival hazard ratio has been released for this arm at all.
HR 0.11 — an unusually large effect for a randomized phase 3A hazard ratio of 0.11 is an extraordinary point estimate from a first interim analysis that triggered early unblinding. Effect sizes from early-stopped analyses are systematically biased upward, so this is best read as a real, IDMC-validated but immature signal — not a final number.
Overall survival
Teclistamab + talquetamab: hazard ratio 0.38 — a 62% reduction in the risk of death. Point estimate only: no confidence interval and no p-value have been released. (J&J topline release)
Regulatory status
TECVAYLI® (teclistamab-cqyv) is FDA approved in two settings: in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) after at least one prior line including a proteasome inhibitor and an immunomodulatory agent (approved 5 March 2026); and as monotherapy after at least four prior lines (accelerated approval October 2022, converted to traditional approval March 2026). TALVEY® (talquetamab-tgvs) is FDA approved as monotherapy after at least four prior lines — this indication remains under accelerated approval (August 2023), based on response rate and durability of response, with continued approval contingent on confirmatory trials. ⚠️ The TECVAYLI + TALVEY combination studied in MonumenTAL-6 is investigational and is NOT FDA approved in any setting, including the 1–4 prior-line population. Talquetamab + pomalidomide is likewise investigational.
What it does not answer
Dr. Henry Fu (Fox Chase Cancer Center) set out the open questions: whether fixed duration drives the efficacy or was simply the strategy studied; whether two years is the optimal duration of T-cell engager therapy; how durable remissions are after stopping; and how this compares with CAR-T or other T-cell engager regimens. No safety data from the trial are public.
Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Top KOLs Discussing MonumenTAL-6
@kansagraMD discloses involvement in the trial — “Grateful to the entire MonumenTAL-6 team … proud to have an opportunity to help advance this amazing therapy”.
MonumenTAL-6 Study Design Slide
Transcribed from the slide image. The per-arm figures (n=265) and N=795 on this slide are planned enrolment from a trial-in-progress presentation, not an actual randomized headcount.
What KOLs Are Saying About MonumenTAL-6
About the MonumenTAL-6 Trial
MonumenTAL-6 is a randomized phase 3 trial run by Janssen Research & Development, LLC (Johnson & Johnson). It asked whether pairing two bispecific antibodies with different targets — teclistamab against BCMA and talquetamab against GPRC5D — could outperform standard triplet regimens in patients whose myeloma has relapsed after one to four prior lines and who have already been exposed to an anti-CD38 antibody and lenalidomide. A second experimental arm paired talquetamab with pomalidomide.
J&J describes MonumenTAL-6 as “the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma” — a sponsor claim, quoted as such.
Trial Design & Reported Results
Study Design
Randomized, open-label phase 3; three arms, 1:1:1; approximately 795 patients (target enrolment), n=265 planned per arm. NCT06208150 · study code 64407564MMY3009.
Population
Relapsed/refractory multiple myeloma after 1–4 prior lines, previously exposed to lenalidomide and an anti-CD38 antibody in any prior line, with progressive disease on or after the last therapy; ECOG 0–2. Patients refractory to anti-CD38 antibodies were permitted — this is an exposure requirement, not a refractoriness requirement. Prior pomalidomide, prior teclistamab and prior GPRC5D-directed therapy were excluded.
Comparator
Investigator's choice of elotuzumab + pomalidomide + dexamethasone (EPd) or pomalidomide + bortezomib + dexamethasone (PVd). Because prior pomalidomide was an exclusion, both options are pomalidomide-based regimens appropriate for a pomalidomide-naive population — J&J describes this as “investigator's choice standard of care”.
Treatment duration
Talquetamab and teclistamab are capped at up to 26 cycles, as tolerated, rather than continuing to progression. With 28-day cycles in the two investigational arms that works out to roughly two years — a figure derived from those two sourced facts, not a duration quoted directly. The cap applies to the bispecific antibodies specifically; pomalidomide in the talquetamab + pomalidomide arm, and the comparator regimens, continue until progression.
Targets
Teclistamab targets BCMA; talquetamab targets GPRC5D — two different myeloma antigens hit at once.
Endpoints
Primary: progression-free survival by independent review committee. Secondary: overall response rate, ≥VGPR, ≥CR, MRD-negative CR, overall survival, PFS2, time to next treatment, patient-reported outcomes and adverse events.
Evidence
Company topline press release, July 23, 2026, first interim analysis. No congress presentation or publication yet; data cut-off not disclosed.
Reported efficacy
Teclistamab + talquetamab: hazard ratio 0.11 (95% CI 0.08–0.16; p<0.0001) — an 89% reduction in the risk of progression or death; overall survival hazard ratio 0.38 — a 62% reduction in the risk of death. Point estimate only: no confidence interval and no p-value have been released.
Talquetamab + pomalidomide: hazard ratio 0.27 (95% CI 0.2–0.35) — a 73% reduction in the risk of progression or death. No p-value disclosed, and no overall-survival hazard ratio has been released for this arm at all.
No median PFS or OS, response rates, MRD data, landmark rates or median follow-up have been released, and no data cut-off was disclosed — so none appear here. (J&J topline release)
Safety
MonumenTAL-6 has not reported trial-specific safety data. The topline release states only that the safety profiles for both investigational arms were “consistent with the known safety profiles of each monotherapy”. No adverse-event rates, no cytokine release syndrome or ICANS incidence and no discontinuation rates from this trial have been disclosed. Every percentage circulating alongside this readout comes from the monotherapy programmes (MajesTEC-1, MajesTEC-3, MonumenTAL-1), not from MonumenTAL-6, and is therefore not reproduced here. Detailed safety data are expected at a future medical meeting.
Prescribing-information note (not a MonumenTAL-6 finding). Both TECVAYLI and TALVEY carry FDA boxed warnings for cytokine release syndrome and neurologic toxicity including ICANS, and are available only through their REMS programme.
MonumenTAL-6 in the News
MonumenTAL-6 FAQ
What did MonumenTAL-6 show?
In a company topline announcement on July 23, 2026, teclistamab plus talquetamab reduced the risk of progression or death by 89% (hazard ratio 0.11) and the risk of death by 62% (hazard ratio 0.38) versus investigator's choice of EPd or PVd, in relapsed/refractory multiple myeloma after 1-4 prior lines. A second experimental arm, talquetamab plus pomalidomide, also beat standard of care (PFS hazard ratio 0.27).
Is this combination FDA approved?
No. TECVAYLI (teclistamab-cqyv) is FDA approved in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) after at least one prior line, and as monotherapy after at least four prior lines. TALVEY (talquetamab-tgvs) is FDA approved as monotherapy after at least four prior lines, an indication that remains under accelerated approval. The teclistamab + talquetamab combination studied in MonumenTAL-6, and this earlier-line 1-4 prior-line setting, are investigational and not FDA approved.
How solid is the evidence so far?
These results come from a company topline press release dated July 23, 2026, reporting the first interim analysis. An Independent Data Monitoring Committee recommended unblinding the study on the strength of the data. The full dataset has not been presented at a congress or published, so median PFS/OS, response rates, safety and the analysis cut-off are not public. The data cut-off date was not disclosed. Every figure on this page is a topline number; treat it accordingly until the full dataset is presented.
Why are KOLs focused on 'fixed duration'?
Both experimental regimens were given for a fixed period of roughly two years rather than until progression. Several physicians called that the most notable design choice. Dr. Henry Fu framed the open question directly: is fixed duration the reason for the efficacy, or simply the strategy that happened to be studied, and is two years the right length?
What questions does MonumenTAL-6 not answer?
Per Dr. Henry Fu (Fox Chase Cancer Center): whether fixed duration drives the efficacy, whether two years is the optimal duration of T-cell engager therapy, how durable remissions are after treatment stops, and how the strategy compares with CAR-T or other T-cell engager regimens. Safety data from the trial are not yet public.
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated July 24, 2026.